Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

doi:10.1158/0008-5472.CAN-20-0141

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

Cancer research - 1 Oct 2020

Pulido Inés, Ollosi Stephen, Aparisi Salvador, Becker Jeffrey H, Aliena-Valero Alicia, Benet Marta, Rodríguez María L, López Adrián, Tamayo-Torres Eva, Chuliá-Peris Lourdes, García-Cañaveras Juan Carlos, Soucheray Margaret, Dalheim Annika V, Salom Juan B, Qiu Wei, Kaja Simon, Fernández-Coronado Javier Alcácer, Alandes Sandra, Alcácer Javier, Al-Shahrour Fátima, Borgia Jeffrey A, Juan Oscar, Nishimura Michael I, Lahoz Agustín, Carretero Julián, Shimamura Takeshi

Abstract excerpt

Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated radiographically, however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR promotes the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Availability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Endothelin-1

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Vascular Endothelial Growth Factor A

Share to Vasoconstriction

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32747363
DOI: 10.1158/0008-5472.CAN-20-0141
PMCID: PMC7541638

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.PMID 32747363Read ↗

Neuroendocrine-like/EMT dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axisSemantic proximity Read ↗

Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.Semantic proximity Read ↗

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.Semantic proximity Read ↗

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.Semantic proximity Read ↗

Epithelial membrane protein-1 is a biomarker of gefitinib resistance.Semantic proximity Read ↗

Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating β2AR signalingSemantic proximity Read ↗

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.